Novo Nordisk has acquired rights to a preclinical drug that could be used to treat non-alcoholic steatohepatitis (NASH), the fatty liver disease that could generate billions of dollars for
Novartis has signalled its strong intentions in the race to develop a treatment for the fatty liver disease, non-alcoholic steatohepatitis (NASH), taking an option on Conatus Pharmaceutical
Genfit is struggling to recruit patients to its phase 3 NASH trial - blaming in part the fierce competition from drug companies developing rival treatments.
NICE has recommended regular NHS funding for Intercept’s Ocaliva for the chronic liver disease primary biliary cholangitis (PBC) in final draft guidance, providing an alternative option for
The venture capital arms of MSD and Amgen have provided $10 million in funding to Culmination Bio, a Utah start-up that aims to build the largest disease-agnostic patient
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio
